News stories about Rite Aid (NYSE:RAD) have trended somewhat positive on Monday, according to Accern Sentiment. The research group rates the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Rite Aid earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned headlines about the company an impact score of 45.9450413413773 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Taking Stock: Rite Aid prescription for profit became a bitter pill (newsok.com)
- Short Interest in Rite Aid (RAD) Increases By 11.9% (americanbankingnews.com)
- Rite Aid (RAD) Reports Narrower-Than-Estimated Loss in Q4 (zacks.com)
- Rite Aid: Good News Overlooked (seekingalpha.com)
- Rite Aid (RAD) Q4 2018 Earnings Conference Call Transcript (finance.yahoo.com)
Rite Aid stock opened at $1.68 on Monday. The company has a market cap of $1,740.26, a P/E ratio of -84.00 and a beta of 1.80. The company has a current ratio of 1.37, a quick ratio of 0.59 and a debt-to-equity ratio of 2.11. Rite Aid has a one year low of $1.38 and a one year high of $4.61.
RAD has been the topic of several research analyst reports. Evercore ISI initiated coverage on Rite Aid in a research note on Thursday, January 4th. They issued an “underperform” rating and a $1.50 price objective on the stock. Zacks Investment Research lowered Rite Aid from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. Finally, Vetr lowered Rite Aid from a “strong-buy” rating to a “buy” rating and set a $2.47 price target on the stock. in a research report on Thursday, January 11th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $2.33.
About Rite Aid
Rite Aid Corporation, through its subsidiaries, operates a chain of retail drugstores in the United States. The company operates through Retail Pharmacy and Pharmacy Services segments. The Retail Pharmacy segment sells prescription drugs; and a range of other merchandise, such as over-the-counter medications, health and beauty aids, personal care items, cosmetics, household items, food and beverages, greeting cards, seasonal merchandise, and other everyday and convenience products.
Receive News & Ratings for Rite Aid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rite Aid and related companies with MarketBeat.com's FREE daily email newsletter.